2-(4-chlorophenyl)-4,5-dimethyl-1,3-oxazole | 832076-74-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-chlorophenyl)-4,5-dimethyl-1,3-oxazole
• 英文别名: 2-(4-chlorophenyl)-4,5-dimethyloxazole；Oxazole, 2-(4-chlorophenyl)-4,5-dimethyl-
• CAS: 832076-74-1
• 化学式: C₁₁H₁₀ClNO
• 分子量: 207.659
• InChiKey: NWPHYKUXOYBFAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-chlorophenyl)-4,5-dimethyl-1,3-oxazole 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 以75%的产率得到4-(bromomethyl)-2-(4-chlorophenyl)-5-methyl-1,3-oxazole
  参考文献：
  名称：

  A New Approach to the Synthesis of 2-Aryl-4-halomethyl-5-methyl-1,3-oxa­zoles by Highly Regioselective Direct Halogenation with NBS or NCS/MeCN

  摘要：

  描述了一种简单高效的合成2-芳基-4-溴甲基-5-甲基-1,3-噁唑2和2-芳基-4-氯甲基-5-甲基-1,3-噁唑3的方法。在温和条件下，2-芳基-4,5-二甲基-1,3-噁唑1与N-溴代琥珀酰亚胺和N-氯代琥珀酰亚胺在乙腈中反应，以中等至良好的收率提供了具有极高区域选择性的4-卤甲基异构体。

  DOI：

  10.1055/s-2004-834862
• 作为产物：
  描述：

  在 ammonium acetate 、 溶剂黄146 作用下， 反应 8.0h， 生成 2-(4-chlorophenyl)-4,5-dimethyl-1,3-oxazole
  参考文献：
  名称：

  A New Approach to the Synthesis of 2-Aryl-4-halomethyl-5-methyl-1,3-oxa­zoles by Highly Regioselective Direct Halogenation with NBS or NCS/MeCN

  摘要：

  描述了一种简单高效的合成2-芳基-4-溴甲基-5-甲基-1,3-噁唑2和2-芳基-4-氯甲基-5-甲基-1,3-噁唑3的方法。在温和条件下，2-芳基-4,5-二甲基-1,3-噁唑1与N-溴代琥珀酰亚胺和N-氯代琥珀酰亚胺在乙腈中反应，以中等至良好的收率提供了具有极高区域选择性的4-卤甲基异构体。

  DOI：

  10.1055/s-2004-834862

文献信息

• Abnormal Diels–Alder Reaction of Oxazoles with 4-Phenyl-3<i>H</i>-1,2,4-triazole-3,5(4<i>H</i>)-dione and Diethyl Azodicarboxylate, and X-Ray Crystal Structure of an Adduct
  作者：Toshikazu Ibata、Hiroyuki Suga、Yasushi Isogami、Hatsue Tamura、Xiaolan Shi

  DOI：10.1246/bcsj.65.2998

  日期：1992.11

  The reaction of substituted oxazoles with 4-phenyl-3H-1,2,4-triazole-3,5(4H)-dione (PTAD) or diethyl azodicarboxylate gave the corresponding 1,2,4-triazoline derivatives through formal [3+2] cycloaddition accompanying ring opening of oxazoles. The molecular structure of an adduct of 5-methoxy-4-methyl-2-(p-tolyl)oxazole with PTAD was determined by means of X-ray crystallography.

  取代的恶唑与 4-苯基-3H-1,2,4-三唑-3,5(4H)-二酮 (PTAD) 或偶氮二甲酸二乙酯反应通过 [3+ 2]伴随恶唑开环的环加成。5-甲氧基-4-甲基-2-（对甲苯基）恶唑与 PTAD 的加合物的分子结构通过 X 射线晶体学确定。
• A series of 2, 4, 5-trisubstituted oxazole: Synthesis, characterization and DFT modelling
  作者：Vinay S. Kadam、Saminaparwin G. Shaikh、Arun L. Patel

  DOI：10.1016/j.molstruc.2016.02.033

  日期：2016.6

  Abstract A new series of 2,4,5-trisubstituted oxazole were synthesized with good yields using simple methodology. All the compounds were thoroughly characterized by IR, NMR (1H and 13C) and mass spectrometry and structures of 2-(4-butyloxyphenyl)-4,5-dimethyloxazole (5b) and 4,5-dimethyl-2-(4-(octyloxy)phenyl)oxazole(5e) were unambiguously determined by X-ray crystallography. Evidently, the crystal

  摘要 采用简单的方法合成了一系列新的2,4,5-三取代恶唑，收率良好。所有化合物均通过 IR、NMR（1H 和 13C）和质谱以及 2-(4-丁氧基苯基)-4,5-二甲基恶唑 (5b) 和 4,5-二甲基-2-(4-(辛氧基）苯基）恶唑（5e）通过 X 射线晶体学明确确定。显然，这些化合物的晶体结构表现出C-H⋯N和C-H⋯O分子间相互作用。这些化合物的电子结构也通过 DFT 在 B3LYP/6-311G ++ 理论水平进行了研究。
• 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
  申请人：Tsubouchi Hidetsugu

  公开号：US20060094767A1

  公开（公告）日：2006-05-04

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物，其通式如下：其中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R2代表—OR3或类似的基团，R3代表氢原子、C1-C6烷基或类似的基团，或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环，其通式为（H）：其中，R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。
• Novel Cyclic Amino Benzoic Acid Derivative
  申请人：Nomura Masahiro

  公开号：US20070249580A1

  公开（公告）日：2007-10-25

  The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C 1 -C 4 alkylene, C 2 -C 4 alkenylene, C 2 -C 4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or —(CH 2 ) n — (n represents 0, 1 or 2); X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and —COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

  本发明涉及循环氨基苯甲酸衍生物，作为人类过氧化物酶体增殖物激活受体（PPAR）激动剂，在治疗脂质代谢异常、糖尿病等方面具有有效性，特别是作为人类PPARα亚型的激动剂，以及其加成盐和含有这些化合物的药物组合物。其中，循环氨基苯甲酸衍生物的一般式（1）表示为[其中，环Ar表示可能具有取代基的芳基；Y表示C1-C4烷基、C2-C4烯基、C2-C4炔基或类似物；Z表示氧原子、硫原子或—（CH2）n—（n表示0、1或2）；X表示氢原子、卤原子、可能带有卤原子取代的低烷基或类似物；R表示氢原子或低烷基，而—COOR代替环W的结合位置的邻位或间位]或其药学上可接受的盐。
• ANTIBACTERIAL AGENTS
  申请人：Brown David Ryall

  公开号：US20100173933A1

  公开（公告）日：2010-07-08

  Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ═C(R 1 )— or ═N—; R 1 is hydrogen or an optional substituent and R 2 is hydrogen, methyl, or fluorine; or R 1 and R 2 taken together are —CH 2 —, —CH 2 CH 2 —, —O—, or, in either orientation, —O—CH 2 — or —OCH 2 CH 2 —; R 3 is a radical of formula -(Alk 1 ) m -(Z) p -(Alk 2 ) n -Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z is —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, —N(CH 2 CH 3 )—, —C(═O)—, —O—(C═O)—, —C(═O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms; Alk 1 and Alk 2 are optionally substituted C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, or —N(CH 2 CH 3 )—; and Q is hydrogen, halogen, nitrile, or hydroxyl or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted bicyclic heterocyclic radical having 5 to 10 ring atoms.

  化学式为（I）的化合物具有抗菌活性：其中R代表氢或1、2或3个可选取代基；W是═C（R1）-或═N-；R1是氢或可选取代基，R2是氢、甲基或氟；或R1和R2一起取-CH2-、-CH2CH2-、-O-，或者，在任何方向上，取-O-CH2-或-OCH2CH2-；R3是公式-(Alk1)m-(Z)p-(Alk2)n-Q的基团，其中m、p和n独立地为0或1，但至少有一个为1，Z是-O-、-S-、-S（O）-、-S（O2）-、-NH-、-N（CH3）-、-N（CH2CH3）-、-C（═O）-、-O-（C═O）-、-C（═O）-O-，或具有3至6个环原子的可选取代的单环碳环或杂环基团；或具有5至10个环原子的可选取代双环杂环基团；Alk1和Alk2是可选取代的C1-C6烷基、C2-C6烯基或C2-C6炔基基团，可以以-O-、-S-、-S（O）-、-S（O2）-、-NH-、-N（CH3）-或-N（CH2CH3）-结尾或被中断；Q是氢、卤素、腈或羟基，或具有3至6个环原子的可选取代的单环碳环或杂环基团；或具有5至10个环原子的可选取代的双环杂环基团。